Spineway (ALSPW) Q1 2025 TU earnings summary

Executive summary

• Q1 2025 revenue reached €2.8 million, down 8% year-over-year due to a high comparison base in Q1 2024.

• Revenue remained stable sequentially from Q4 2024.

• Export sales outside Europe grew 9% year-over-year, driven by Asia and Middle East-Africa regions.

Financial highlights

• Q1 2025 revenue: €2.8 million, compared to €3.07 million in Q1 2024.

• Export sales accounted for 50% of total revenue in Q1 2025.

• France revenue stable (-3%), Europe revenue declined sharply (-37%) year-over-year.

Outlook and guidance

• Full-year 2025 growth target confirmed.

• Ongoing rollout of multi-year market approval program in key markets.

• Strategic focus on becoming a major player in less invasive spine treatments.